XBiotech Inc.
NASDAQ:XBITBiotechnology
-$0.02 today
- Market cap
- $52.74M
- Beta
- 0.84
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.32
Volume 0.06M
Average 0.03M
XBIT Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
XBiotech Inc.NASDAQ: XBIT
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures turns positive
Q1 FY2026 capital expenditures was $0, compared with -$94K a year earlier. Trailing-twelve-month capital expenditures was -$195K. Over 3 fiscal years it compounded at -20.9% a year.
Context
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly capital expenditures holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$48.75K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (289K) USD
- Year-over-year change
- +77.8%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (289K) | +77.8% |
| FY2024 | 2024-12-31 | (1.3M) | -260.2% |
| FY2023 | 2023-12-31 | (362K) | +38.1% |
| FY2022 | 2022-12-31 | (585K) | +83.4% |
| FY2021 | 2021-12-31 | (3.53M) | — |
Capital Expenditures vs competitors
How XBIT compares with its peers on the latest reported figures
- XBIT's LTM Mar 2026 capital expenditures of $195K is the 4th largest of the 9 companies compared; the peer median is $6.28K.
- Its year-over-year change of -82.9% is the 4th highest of 6, against a peer median of -36.7%.
- Over three fiscal years its annual growth of -20.9% compares with a peer median of -53.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $2.95M | -36.7% | +1.4% | 32.2% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.63M | -19.2% | -8.3% | — |
| LTM Mar 2026 | $283K | -88.1% | -53.0% | — | |
| LTM Mar 2026 | $195K | -82.9% | -20.9% | — | |
| LTM Jun 2024 | $12.55K | — | -70.9% | 1.5% | |
| LTM Apr 2026 | $5.33K | +105.8% | -59.4% | 0.3% | |
| LTM Mar 2026 | $8 | -100.0% | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding XBIT) | $6.28K | -36.7% | -53.0% | 0.9% | |
Competitors are the stored peer set for XBIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.41M) | (32.9M) | (24.56M) | (38.53M) | (45.54M) |
| Depreciation & Amortization | 2.65M | 2.61M | 1.74M | 1.75M | 1.69M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 5K |
| Stock-Based Compensation | 4.46M | 5.06M | 3.26M | 1.75M | 3.62M |
| Change in Working Capital | 79.75M | 7.6M | 2.72M | (1.46M) | 3.64M |
| Accounts Receivables | 1.73M | 7.34M | 829K | 77K | 574K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (514K) | 357K | 91K | (364K) | (688K) |
| Other Working Capital | 78.53M | (97K) | 1.8M | (1.17M) | 3.75M |
| Other Non-Cash Items | 4.46M | 2.8M | (1.89M) | 5.53M | (3.33M) |
| Operating Cash Flow | 69.45M | (14.82M) | (18.73M) | (30.96M) | (39.92M) |
| Capital Expenditures | (3.53M) | (585K) | (362K) | (1.3M) | (289K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (63.31M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 61.86M | 0 | 0 |
| Investing Cash Flow | (3.53M) | (63.89M) | 61.5M | (1.3M) | (289K) |
| Debt Repayment | 0 | 0 | 0 | 10.25M | (10.25M) |
| Common Stock Issued | 0 | 0 | 5K | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (75M) | 0 | 0 | 0 | 0 |
| Other Financing Activities | 8M | 0 | (14K) | 200K | 0 |
| Financing Cash Flow | (67.01M) | 0 | (9K) | 10.45M | (10.25M) |
| Effect of Forex Changes | 705K | (961K) | (46K) | (5.53M) | 3.33M |
| Net Change in Cash | (383K) | (79.68M) | 42.72M | (27.35M) | (47.13M) |
| Free Cash Flow | 65.92M | (15.41M) | (19.09M) | (32.27M) | (40.21M) |
XBiotech Inc.
NASDAQ:XBIT
Intrinsic Alpha fair value
Locked
Current Price
$1.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.